ADjunctive coRticosteroid trEatment iN criticAlly ilL Patients With Septic Shock
NCT01448109 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 3800
Last updated 2017-12-12
Summary
The purpose of this study is to find out whether adult patients admitted to the Intensive Care Unit with septic shock who are given hydrocortisone compared to placebo (a dummy solution), will have an improved rate of survival 90 days later.
Septic shock is the result of an infection, which triggers a complex response by the body (the inflammatory response) that causes a decrease in blood pressure and subsequently one or more organ systems to fail when blood supply to these organs is reduced. This may result in poor recovery and death. About a quarter of the people who suffer septic shock that is not rapidly reversed, will die.
When patients are admitted to Intensive Care with sepsis and/or septic shock they receive a number of therapies. These include fluids given through a drip, antibiotics, drugs to boost your blood pressure and other organ systems.
In addition to these therapies, steroids (hydrocortisone) are sometimes administered. Whether steroids are useful or not in the treatment of severe infections has been studied for more than 50 years. Previous research has suggested that the use of low dose steroid may have shortterm benefits in improving the circulation. However, there is no agreement amongst doctors around the world about whether treatment with or without low dose steroids improves the overall recovery and survival in patients with septic shock. This study would allow doctors to make informed decisions about whether the addition of low dose steroid therapy is better for patients with septic shock in intensive care.
The study will include 3800 intensive care patients who have septic shock. Each enrolled patient will be randomised to receive either Hydrocortisone 200mg or placebo daily for 7 days as a continuous intravenous infusion while in intensive care. The patient will be followed for 90 days. If the patient is discharged prior to 90 days a telephone call will be made for the followup information. At six months the patient will be contacted again for completion of a quality of life questionnaire.
Conditions
- Septic Shock
Interventions
- DRUG
-
Hydrocortisone
Hydrocortisone 100mg vial (blinded) is reconstituted with 2ml of water for Injection, agitated for 20 seconds, rested for 3 minutes, contents of vial aspirated and added to 100ml bag of normal saline or 5% dextrose and given intravenously as a continuous infusion at rate of 200mg/per day for 7 days.
- DRUG
-
Sterile air filled vial
the "sterile air filled vial" (blinded) is reconstituted with 2ml of water for Injection, agitated for 20 seconds, rested for 3 minutes, contents of vial aspirated and added to 100ml bag of normal saline or 5% dextrose and given intravenously as a continuous infusion. 2 sterile air filled vials per day for 7 days
Sponsors & Collaborators
-
National Health and Medical Research Council, Australia
collaborator OTHER -
Australian and New Zealand Intensive Care Society Clinical Trials Group
collaborator NETWORK -
The George Institute
lead OTHER
Principal Investigators
-
Balasubramanian Venkatesh · The George Institute
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-06-13
- Primary Completion
- 2017-10-22
- Completion
- 2017-11-20
Countries
- Australia
- Denmark
- New Zealand
- Saudi Arabia
- United Kingdom
Study Locations
More Related Trials
-
Early Versus Conventional Cessation of Hydrocortisone in Septic Shock
NCT05818826 ·Status: RECRUITING ·Phase: PHASE2
-
Hydrocortisone Versus Hydrocortisone Plus Fludrocortisone for the Treatment of Adrenal Insufficiency in Severe Sepsis
NCT00368381 ·Status: WITHDRAWN ·Phase: PHASE4
-
HCT+F vs. HCT Alone in Critically Ill Medical Septic Shock Patients
NCT03710187 ·Status: COMPLETED ·Phase: PHASE2
-
Stress Doses of Hydrocortisone on Coagulation Dysfunction in Patients With Septic Shock
NCT02266589 ·Status: COMPLETED ·Phase: PHASE3
-
Hemodynamic and Inflammatory Effects of Abrupt Versus Tapered Corticosteroid Discontinuation in Septic Shock
NCT01150409 ·Status: TERMINATED ·Phase: PHASE4
-
Days Alive and Out of Hospital for Patients With Sepsis
NCT04567433 ·Status: COMPLETED
-
Septic Shock em Steroids
NCT01047670 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Adrenal Insufficiency in Septic Shock
NCT00842933 ·Status: TERMINATED ·Phase: PHASE4
-
Evaluation of the Role of Hydrocortisone Either Alone or Combined With Fludrocortisone in the Outcome of Septic Shock in Adults
NCT04492280 ·Status: COMPLETED ·Phase: PHASE4
-
Impact of Hydrocortisone Administration on White Blood Cell Gene Expression in Patients With Severe Sepsis
NCT00185783 ·Status: COMPLETED
-
Hydrocortisone 50 mg Every 6 Hours Compared to Hydrocortisone 300 mg Per Day in Treatment of Septic Shock.
NCT02768740 ·Status: COMPLETED ·Phase: PHASE4
-
Cortisol Control of Human Inflammatory Responses to Endotoxin
NCT00396344 ·Status: COMPLETED ·Phase: NA
-
Rapid Recognition of Corticosteroid Resistant or Sensitive Sepsis
NCT04280497 ·Status: RECRUITING ·Phase: NA
-
The Vitamin C, Hydrocortisone and Thiamine in Patients With Septic Shock Trial
NCT03333278 ·Status: COMPLETED ·Phase: PHASE2
-
Hydrocortisone for COVID-19 and Severe Hypoxia
NCT04348305 ·Status: COMPLETED ·Phase: PHASE3
-
Combination of Corticotherapy and Intensive Insulin Therapy for Septic Shock
NCT00320099 ·Status: COMPLETED ·Phase: PHASE3
-
Early Intravenous Hydrocortisone in Sepsis
NCT06217939 ·Status: RECRUITING ·Phase: NA
-
Adjunctive Granisetron Therapy in Patients With Sepsis or Septic Shock
NCT03924518 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of Hydrocortison Treatment on Angiotensin II and Angiotensin II Receptors in Patients With Septic Shock
NCT04647552 ·Status: COMPLETED
-
Effect of Hydrocortison on Post-ischemic Flow-mediated Dilation and on Thenar Oxygen Saturation in Human Septic Shock.
NCT01817153 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Effects of Fludrocortisone on Norepinephrine-mean Arterial Pressure Dose-response in Septic Shock
NCT02069288 ·Status: WITHDRAWN ·Phase: PHASE3
-
Effects of Intravenous Metabolic Recovery Agent in Elderly Septic Patients on Prognosis and Microcirculation.
NCT06723626 ·Status: RECRUITING ·Phase: NA
-
Safety and Efficacy of Extracorporeal Cytokine Hemoadsorption in Septic Shock in Critically Ill Cirrhotics
NCT03866083 ·Status: UNKNOWN ·Phase: NA
-
Gender-based Differences in the Outcome of the Treatment of Persistent Septic Shock With Hydrocortisone
NCT06537180 ·Status: COMPLETED
-
Triple Therapy in Septic Shock Patients
NCT04508946 ·Status: COMPLETED ·Phase: PHASE3